| Similar Articles |
|---|
 |
The Motley Fool
December 12, 2008
Brian Orelli |
An EXELent Drug Deal Exelixis picks up $195 million in cash in a licensing deal with Bristol-Myers Squibb.   |
The Motley Fool
December 26, 2007
Brian Lawler |
Exelixis Awaits Bristol-Myers Decision Even if Bristol-Myers Squibb decides to discontinue their partnership, it might not mean the end of the road for Exelixis' cancer treatment. |
The Motley Fool
November 19, 2010
Brian Orelli |
Exelixis: Up 32% With Room to Run It was only a phase 2 trial, after all. |
The Motley Fool
July 22, 2008
Brian Lawler |
Anxiously Awaiting Exelixis Pivotal clinical trial results for a top drug are finally within sight. Investors, take note. |
The Motley Fool
January 3, 2007
Brian Lawler |
Exelixis Busy Selling Its Wares Exelixis inked another development deal with biopharma powerhouse Genentech. Investors, take note. |
The Motley Fool
February 15, 2011
Rich Smith |
What's Behind the Run-Up at Exelixis? One word: earnings. Shares of this tiny drug developer have taken off like a rocket. |
The Motley Fool
December 17, 2007
Brian Lawler |
Glaxo, Exelixis Trade Gifts Glaxo announces that it will take over development of a lead Exelixis drug. |
The Motley Fool
November 7, 2007
Brian Lawler |
Following Up on Exelixis Budding development stage pharma Exelixis announces its third-quarter financial results and updates investors on what they can expect for the rest of the year. |
The Motley Fool
June 5, 2007
Brian Lawler |
Exelixis Presents The pharmaceutical presents data from 2 of its top drug candidates at ASCO. Investors, take note. |
The Motley Fool
June 30, 2010
Ryan McBride |
Reports: Biogen Picks Exelixis Chief George Scangos as New CEO George Scangos, a microbiologist by training, has been CEO of the South San Francisco-based cancer drug developer Exelixis since 1996, and takes over at Biogen immediately. |
The Motley Fool
June 10, 2008
Brian Lawler |
Exelixis Secures Its Future In one of the more complicated financing deals ever made by a development-stage drugmaker, Exelixis brings in enough cash to keep guiding its lead drugs closer to market. |
The Motley Fool
May 29, 2009
Brian Orelli |
This Company Is Hot and Going Places Pharma company sanofi-aventis licenses a program, including two phase 1 compounds from Exelixis. |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
The Motley Fool
May 10, 2005
Charly Travers |
The Future of Cancer Therapy Biotech firm Exelixis is blazing a trail for long-term success. Should investors take notice? |
The Motley Fool
June 6, 2011
Luke Timmerman |
Exelixis Zeroes In on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients Is Exelixis' risky bet about to pay off? |
The Motley Fool
April 21, 2011
Brian Orelli |
Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested. |
The Motley Fool
June 6, 2006
Brian Lawler |
Exelixis' Continued Excellence The company reported preliminary phase 1 results for three of its lead compounds. Until investors see the results from phase 2 trials, they should chalk Exelixis up as a promising young biotech company whose successes they will patiently cheer for from the sidelines. |
The Motley Fool
April 29, 2004
Bill Mann |
Schizophrenia Saves Bristol-Myers Big gains in currencies and schizophrenia drugs help offset some key losses. |
The Motley Fool
September 28, 2006
Brian Lawler |
Exelixis' Growing Share Count The developing biopharmaceutical company announces a share offering. |
The Motley Fool
October 26, 2007
Billy Fisher |
A Quarter to Boast About at Bristol Bristol-Myers announces a 22% rise in third-quarter revenue as Plavix sales continue to rise. Investors, take note. |
The Motley Fool
October 1, 2008
Brian Orelli |
3 Drugmakers With Multiple Shots on Goal Well-stocked pipelines could kick these drugmakers into super-high gear. |
The Motley Fool
September 8, 2011
Brian Orelli |
Delayed Data Coming Soon? EXELent! Exelixis should have data on cabozantinib early in the fourth quarter. |
The Motley Fool
April 2, 2008
Brian Lawler |
A Slate of Data for Exelixis Exelixis will present analyses of study data at the American Society of Clinical Oncology in May for all of its lead cancer-fighting compounds. Investors, take note. |
The Motley Fool
September 24, 2007
Brian Lawler |
An Array of Good News Small pharmaceutical firm Array BioPharma signs a big partnership deal with Celgene. Investors, take note. |
BusinessWeek
February 26, 2007
Arlene Weintraub |
The Power Of The Pipeline Bristol-Myers Squibb is beset with troubles, but its new-drug potential makes it a target. |
The Motley Fool
November 20, 2006
Brian Lawler |
One-and-a-Half Setbacks for Exelixis Drug development is a long process usually involving many setbacks and failures, even for the most successful drug makers. Investors in this biotech shouldn't worry too much about this one. |
The Motley Fool
September 7, 2010
Luke Timmerman |
ZymoGenetics, Seattle Biotech Pioneer, Acquired by Bristol-Myers for $885 Million The two companies have gotten to know each other quite well since January 2009, when Bristol agreed to pay as much as $1.1 billion for the right to co-develop and co-market a drug for hepatitis C. |
The Motley Fool
August 8, 2007
Brian Lawler |
Array's Bright Pipeline Array BioPharma announces its goals for the months ahead in its fourth-quarter results. What is interesting is the varied mix of new compounds in their pipeline. |
The Motley Fool
December 21, 2011
Brian Orelli |
A Biotech Garage Sale Exelixis sells off a preclinical program. |
The Motley Fool
March 31, 2008
Brian Lawler |
SGX Down for the Count? The pharmaceutical's lead drug fares poorly in clinical testing. |
The Motley Fool
November 26, 2010
Brian Orelli |
Black Friday Biotech Bargains Drugmakers on sale. |
The Motley Fool
December 17, 2008
Brian Orelli |
A Super-Cheap Call Option GlaxoSmithKline announces it's partnering up with tiny Dynavax Technologies to develop up to four drugs for autoimmune and inflammatory diseases. The pay-if-the-drug-works scheme should pay off. |
The Motley Fool
November 1, 2011
Brian Orelli |
Not Such an Excellent Outcome With the FDA Exelixis gets knocked down for not getting an SPA. |
The Motley Fool
October 8, 2010
Luke Timmerman |
Bristol-Myers Almost Ready to Seal the Deal With ZymoGenetics ZymoGenetics, one of the driving forces of Seattle biotech the past 30 years, is about to become a thing of the past. |
The Motley Fool
December 27, 2011
Brian Orelli |
Exelixis 2011: Not What the Doctor Ordered A tale of an inability to get a Special Protocol Assessment from the FDA. |
The Motley Fool
October 8, 2007
Charly Travers |
Scanning 4 Biotechs There are major events set for the following biotech companies during this quarter. Investors, take note: BioMarin Pharmaceutical... Exelixis... Neurocrine Biosciences... Pain Therapeutics... |
The Motley Fool
January 28, 2009
Brian Orelli |
A Mini-Pfizer in the Making Bristol-Myers Squibb looks like its setting itself up to be the next Pfizer. |
The Motley Fool
July 30, 2007
Brian Lawler |
Bristol-Myers Isn't Standing in Place Brighter days seem ahead for Bristol-Myers Squibb, now that recent litigation has taken a major turn for the better. |
The Motley Fool
January 28, 2011
Brian Orelli |
Looking Ahead at Bristol-Myers Product approvals now will help with the upcoming patent cliff. |
The Motley Fool
April 28, 2011
Brian Orelli |
1 Year to P-Day, Bristol-Myers Squibb Looks Just Fine New drugs should help cushion the fall from the loss of Plavix. |
The Motley Fool
May 31, 2011
Brian Orelli |
Profit From This Growing Drug Trend Cancer drugs press on. |
The Motley Fool
August 31, 2007
Brian Lawler |
4 Biotech Bets Under $10 Development stage drugmakers are among the most exciting stocks to follow. Here are four that are all worth a place on your watch list: Pharmacopeia, Pain Therapeutics, Pharmasset, and SGX Pharmaceuticals. |
The Motley Fool
December 18, 2007
Brian Orelli |
Bristol-Myers' Sleeker Image Just 12 days after announcing its restructuring plan, Bristol-Myers Squibb has found a buyer for its medical-imaging division and plans to close the deal by the end of next month. |
The Motley Fool
March 17, 2008
Brian Orelli |
Drugmakers That Make Rivals Green with Envy A look at some drugmakers with cash to spend: Pfizer...Wyeth... Novartis... Amylin Pharmaceuticals... Elan...Vertex Pharmaceuticals... Exelixis... |
The Motley Fool
January 29, 2009
Brian Orelli |
A Secondary Offering? In This Market? For these pharma companies, when the value of their company drops even though they haven't had any bad news, the secondary-offering step becomes very costly for current shareholders. |
The Motley Fool
June 30, 2010
Brian Orelli |
Is Bristol-Myers Squibb a Buy? Bristol-Myers is a better buy than Eli Lilly for one major reason: its resources. |
The Motley Fool
January 28, 2011
Brian Orelli |
Value Investing, Biotech Style Biotech investors should regard every binary event as a varying degree of confidence in a positive or negative result. |
The Motley Fool
November 27, 2009
Brian Orelli |
Biotech Bargains for Your Portfolio Everyone is looking for bargains this time of year. That includes pharmaceutical giants looking to pick up some biotechs on the discount rack, and investors trying to get there first. |
The Motley Fool
November 18, 2008
Brian Orelli |
Icahn's Next Biotech Adventure With ImClone done, he's got his eye focused elsewhere. |
The Motley Fool
October 24, 2011
Brian Orelli |
Biotech Blunder Turned 20% Overnight Gain Exelixis gets good data, even if it wasn't exactly what it was expecting. |
